Q3 earnings — pre-call memo

Heading into Thursday, our story is straightforward: revenue beat, EBITDA expanded year-over-year, and we're guiding analysts toward a moderate uptick in CAPEX in Q4 as the Manchester facility goes live. The single number sell-side will focus on is the EBITDA margin — please commit it to memory before the call.

On capital allocation: the board approved an incremental CAPEX envelope last month, which I will frame as "investing through the cycle." Expect at least one analyst to push on ROIC, because the obvious follow-up is whether the new spend will dilute returns. The honest answer is that the projects clearing our internal hurdle rate show ROIC north of 14% on a five-year basis, comfortably above weighted cost of capital. We've also stress-tested the NPV under three demand scenarios; even the bear case is meaningfully positive.

If anyone asks about the deferred CAPEX from Q2 — and someone will — the talking point is that the slippage was driven by permitting in the EU, not by deteriorating economics. The underlying NPV of those projects is unchanged. EBITDA conversion to free cash flow is the slide I'd like to spend the most time on; the bridge slide team has cleaned it up since the dry run.

Finally: do not get baited into a debate about EBITDA as a quality-of-earnings measure. Acknowledge the critique, point to the GAAP reconciliation in the appendix, and pivot back to ROIC and NPV. Those are the two metrics that travel best with long-only investors, and they are the ones that will move the stock on Friday.